Evaluation of Creatine Analogues as a New Class of Anticancer Agents Using Freshly Explanted Human Tumor Cells
The DOI matches its Crossref record.
Abstract
BACKGROUND: The creatine kinase (CK) isozymes and their substrates, creatine and creatine phosphate, are believed to play a pivotal role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, and brain. This enzyme system may also be involved in the process of cellular transformation. Inhibition of tumor cell growth by creatine analogues has been observed and may be due to the ability of these analogues to impair cellular energy generation and utilization. PURPOSE: An in vitro human tumor colony-forming assay was used to predict the clinical usefulness of creatine analogues as anticancer agents. METHODS: The ability of cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) and homocyclocreatine (1-carboxyethyl-2-iminoimidazolidine) to inhibit the growth of cells prepared from tumor samples taken directly from patients was evaluated by quantitative measurement of colony formation in a soft-agar cell culture assay system. Cyclocreatine was tested in this human tumor colony-forming assay at concentrations ranging from 0.067 to 20 mM against 128 tumor samples, 51 of which formed colonies in the assay and were considered evaluable. Homocyclocreatine was similarly tested at concentrations from 0.2 to 20 mM against 139 tumor samples; 54 were considered evaluable. The colony-forming assay was also used to compare the efficacy of the creatine analogues to representatives from the six major classes of standard chemotherapeutics (alkylating agents, antimetabolites, DNA intercalators, platinum compounds, topoisomerase inhibitors, and tubulin-interacting agents). In addition, CK levels were measured in 192 tumor samples that were taken from 166 patients. RESULTS: Cyclocreatine and homocyclocreatine, at concentrations previously achieved in animal tissues (7-20 mM), had antitumor activity against 19% and 50%, respectively, of tumor samples that formed colonies in the assay. Cyclocreatine was effective against a subset of tumors sensitive to homocyclocreatine (P = .023; Fisher's exact test), which was the more potent creatine analogue in this assay (P < .001; McNemar's test). No relationships were seen between tumor samples sensitive to the creatine analogues and those sensitive to standard chemotherapeutics. Pairwise Wilcoxon rank sum tests indicated that CK activity was significantly higher in tumors with any growth in the colony assay compared with tumors that did not grow (P < .025). CONCLUSIONS: The creatine analogues, cyclocreatine and homocyclocreatine, effectively reduced colony formation of freshly explanted human tumor cells. The mechanism of action or resistance to these compounds seems to differ from those of standard chemotherapeutics. IMPLICATIONS: Creatine analogues that may alter the energy status of the tumor cell potentially represent promising new anticancer agents that function through a unique mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950
Self-citationTubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
Jordan, A., Hadfield, J. A., Lawrence, N. J., & McGown, A. T. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u · Cited by 673
Oral creatine supplementation and skeletal muscle metabolism in physical exercise
Mesa, J. L. M., Ruiz, J. R., Gonz??lez-Gross, M. M., Guti??rrez S??inz, ?., & Castillo Garz??n, M. J. (2002) · Sports Medicine · doi:10.2165/00007256-200232140-00003 · Cited by 103
Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis
Li, X.-H., Chen, X.-J., Ou, W.-B., Zhang, Q., Lv, Z.-R., Zhan, Y., Ma, L., Huang, T., Yan, Y.-B., & Zhou, H.-M. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.02.003 · Cited by 74
Patra, S., Ghosh, A., Roy, S. S., Bera, S., Das, M., Talukdar, D., Ray, S., Wallimann, T., & Ray, M. (2012) · Amino Acids · doi:10.1007/s00726-011-0974-3 · Cited by 64
“Interestingly normal cell lines that express high CK level were not inhibited by cyclocreatine (Martin et al. 1994).”
Background
Metadata
- Authors
- Martin, K. J., Chen, S.-F., Clark, G. M., Degen, D., Wajima, M., Von Hoff, D. D., & Kaddurah-Daouk, R.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-04-20
- Volume
- 86
- Issue
- 8
- Pages
- 608-613
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2153853205
- Cited by
- 43
- References
- 0
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Creatine Analogues as a New Class of Anticancer Agents Using Freshly Explanted Human Tumor Cells. https://app.cochat.ai/papers/10.1093/jnci/86.8.608
- The paper
- Martin, K. J., Chen, S.-F., Clark, G. M., Degen, D., Wajima, M., Von Hoff, D. D., & Kaddurah-Daouk, R. (1994). Evaluation of Creatine Analogues as a New Class of Anticancer Agents Using Freshly Explanted Human Tumor Cells. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/86.8.608
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.